Monoclonal Antibodies Targeting erbB-2 Receptor and Tumor Growth
Author Information
Author(s): I.-M. Harwerth, W. Wels, J. Schlegel, M. Muller, N.E. Hynes
Primary Institution: Friedrich Miescher Institute
Hypothesis
Can monoclonal antibodies specific to the erbB-2 receptor inhibit tumor growth in vivo?
Conclusion
The monoclonal antibodies FWP51 and FSP77 significantly delayed tumor growth in mice but were not curative.
Supporting Evidence
- Two antibodies, FWP51 and FSP77, inhibited the onset of tumor growth.
- The combination of FWP51 and FSP77 was more effective than either antibody alone.
- Treatment with FRP5 and FSP16 did not affect tumor growth.
- Antibody treatment led to a reduction in erbB-2 receptor levels.
Takeaway
Scientists tested special antibodies to see if they could stop tumors from growing in mice, and they found that two of the antibodies worked well.
Methodology
The study involved injecting mice with tumor cells and administering monoclonal antibodies to observe their effects on tumor growth.
Limitations
The treatment was not curative, and tumors regrew within two weeks after the final treatment.
Participant Demographics
Athymic nude mice aged 10 to 12 weeks were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website